Humana (NYSE:HUM) Price Target Raised to $393.00

Humana (NYSE:HUM) had its price objective upped by JPMorgan Chase & Co. from $316.00 to $393.00 in a research report released on Monday morning,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the insurance provider’s stock.

Several other research firms have also issued reports on HUM. Wells Fargo & Company upgraded shares of Humana from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $227.00 to $502.00 in a report on Monday, July 13th. Leerink Partners upgraded shares of Humana from a “market perform” rating to an “outperform” rating and set a $513.00 price target on the stock in a report on Thursday, July 30th. Guggenheim increased their price objective on shares of Humana from $269.00 to $471.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Evercore raised shares of Humana from an “in-line” rating to an “outperform” rating and set a $480.00 price objective for the company in a research note on Wednesday, July 29th. Finally, Raymond James Financial lowered Humana from an “outperform” rating to a “market perform” rating in a research report on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, fourteen have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $395.22.

Humana Stock Performance

NYSE:HUM opened at $388.86 on Monday. The stock’s fifty day moving average is $380.56 and its 200 day moving average is $274.05. Humana has a fifty-two week low of $163.11 and a fifty-two week high of $428.88. The firm has a market capitalization of $46.69 billion, a PE ratio of 36.79, a PEG ratio of 2.13 and a beta of 0.72. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.74 and a current ratio of 1.74.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.27 by $0.34. The company had revenue of $40.89 billion during the quarter, compared to the consensus estimate of $40.58 billion. Humana had a return on equity of 11.20% and a net margin of 0.88%.Humana’s revenue was up 26.2% on a year-over-year basis. During the same period last year, the company earned $6.27 earnings per share. On average, sell-side analysts anticipate that Humana will post 9.09 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in HUM. Revolve Wealth Partners LLC bought a new position in Humana in the 4th quarter worth about $202,000. Woodline Partners LP raised its stake in shares of Humana by 460.0% during the first quarter. Woodline Partners LP now owns 10,192 shares of the insurance provider’s stock valued at $2,697,000 after acquiring an additional 8,372 shares in the last quarter. Sivia Capital Partners LLC boosted its holdings in shares of Humana by 53.7% in the second quarter. Sivia Capital Partners LLC now owns 1,293 shares of the insurance provider’s stock valued at $316,000 after purchasing an additional 452 shares during the period. Cresset Asset Management LLC boosted its holdings in shares of Humana by 10.3% in the second quarter. Cresset Asset Management LLC now owns 2,369 shares of the insurance provider’s stock valued at $581,000 after purchasing an additional 222 shares during the period. Finally, WINTON GROUP Ltd grew its position in shares of Humana by 58.5% during the 2nd quarter. WINTON GROUP Ltd now owns 2,381 shares of the insurance provider’s stock worth $582,000 after buying an additional 879 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.